提高急性缺血性卒中静脉溶栓有效性和安全性的研究进展  

Study Progress of Improvement of Safety and Effi cacy of Intravenous Thrombolysis on Acute Ischaemic Stroke

作　　者：吴岩峰[1] 刘庆萍[1] 丁红[1] 

机构地区：[1]南京医科大学第二附属医院神经科,南京210003

出　　处：《中国卒中杂志》2016年第2期126-130,共5页Chinese Journal of Stroke

摘　　要：重组组织型纤溶酶原激活剂(recombinant tissue plasminogen activator alteplase,rt-PA)是目前急性缺血性卒中时间窗内静脉溶栓最有效的治疗药物,然而,静脉溶栓也伴随着出血转化、症状性颅内出血风险的增加,导致患者预后不良,甚至死亡。因此,研究静脉溶栓治疗及预后的影响因素,提高静脉溶栓治疗的有效性及安全性,对急性缺血性卒中患者的预后有着重大意义。The recombinant tissue plasminogen activator alteplase（rt-PA） is the most effective therapeutic drug used in intravenous thrombolysis for patients with acute ischaemic stroke presenting within 4.5 h after symptom onset. Nevertheless, intravenous thrombolysis is accompanied with hemorrhagic transformation（HT）, increased risk of symptomatic intracranial haemorrhage（s ICH）, poor prognosis and even deaths. Therefore, study on infl uential factors on treatment and prognosis and improvement of effi cacy and safety of intravenous thrombolysis has important signifi cance for prognosis of patients with acute ischemic stroke.

关 键 词：急性缺血性卒中 静脉溶栓 重组组织型纤溶酶原激活剂 有效性 安全性 

分 类 号：R743.3[医药卫生—神经病学与精神病学]